Medtronic sees disappointing results from newly-acquired AVE
This article was originally published in Clinica
Executive Summary
Medtronic's third-quarter revenues from stent manufacturer Arterial Vascular Engineering, which it bought late last year for $3.7 billion, will be below expectations. AVE's stent sales fell by 35% compared with the second quarter.